Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- JCR Completes Manufacturing Facility for EPO Biosimilar
September 27, 2010
- Symposiasts Call for Unification of Clinical Research, Trials
September 27, 2010
- Novartis to Keep Weighted Average Invoice Price Unchanged: Mr Mitani
September 27, 2010
- Two GM Mice Lost at Kyowa Kirin's Research Center
September 27, 2010
- Tadaharu Goto Appointed New JPMA Director General
September 27, 2010
- Eisai to Apply for Eszopiclone within FY2010
September 27, 2010
- Mediceo Encourages Its MSs to Take Exam for MR Certification
September 27, 2010
- Agensys Begins PI for AGS-16M8F for RCC
September 27, 2010
- Emerging Countries Drive Global Drug Industry: Ms Chui of IMS
September 27, 2010
- Abstract of PII for CBP501 Presented at IMIG2010: CanBas
September 27, 2010
- Prof. Morishita Calls For Creation of Environment Friendly to Bioventures
September 27, 2010
- 30% Market Share for Generics Unlikely to Be Achieved: Mr Mitsuhara
September 27, 2010
- Rozerem Ranked No. 1 in Both HP, GP Markets: RepTrack Survey
September 27, 2010
- Korosho Confirms “Principle of Nondiscrimination”for Generics Applied by Indian Firms
September 27, 2010
- Ritsuo Hosokawa Appointed New Health Minister
September 27, 2010
- Taiyo, Kyowa Should Be More Severely Punished: Nichibyokyo
September 27, 2010
- Bendamustine Launched in Singapore: SymBio, Eisai
September 27, 2010
- The Pharma Gospel of Praise
Philip Carrigan
Partner, Optia Partners
philip@optiapartners.com
September 27, 2010
- Daiichi Sankyo Wins Appellate Court Litigation against Mylan
September 27, 2010
- Torisel Ensures Good Compliance with IV Infusion Once a Week: Prof. Horie
September 27, 2010
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…